Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Cash from Investing Activities came in at -$5.3 million in Q1 2026, down 115.44% year-on-year from $34.6 million in Q1 2025, and down 113.69% quarter-over-quarter from $39.0 million in Q4 2025.

Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$5.3 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 115.44% year-over-year to -$5.3 million in Q1 2026; TTM through Mar 2026 was $178.8 million, a 338.76% increase from a year earlier, with the FY2025 full-year figure at $218.7 million, up 387.53% from the prior year.
  • Cash from Investing Activities retreated to -$5.3 million in Q1 2026 per SRRK's latest filing, from $39.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $90.0 million in Q1 2023 and bottomed at -$195.4 million in Q4 2024.
  • The 5-year median for Cash from Investing Activities is $33.4 million (2024), against an average of $396411.8.
  • Across the five-year window, Cash from Investing Activities tumbled 32733.77% in 2023 and jumped 516.71% in 2024, its largest moves.
  • Year by year, Cash from Investing Activities stood at $77000.0 in 2022, then tumbled by 32733.77% to -$25.1 million in 2023, then plunged by 677.5% to -$195.4 million in 2024, then soared by 119.95% to $39.0 million in 2025, then plunged by 113.69% to -$5.3 million in 2026.
  • Per Business Quant, the three latest SRRK Cash from Investing Activities figures stand at -$5.3 million (Q1 2026), $39.0 million (Q4 2025), and $59.7 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 172.62 Mn
10 Scholar Rock Holding 6.32 Bn 6.32 Bn - -5.34 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.34 Mn
Mar 31, 2026 -5.34 Mn
Dec 31, 2025 38.97 Mn
Dec 31, 2025 38.97 Mn
Sep 30, 2025 59.70 Mn
Sep 30, 2025 59.70 Mn
Jun 30, 2025 85.47 Mn
Jun 30, 2025 85.47 Mn
Mar 31, 2025 34.55 Mn
Mar 31, 2025 34.55 Mn
Dec 31, 2024 -195.37 Mn
Dec 31, 2024 -195.37 Mn
Sep 30, 2024 35.31 Mn
Sep 30, 2024 35.31 Mn
Jun 30, 2024 50.62 Mn
Jun 30, 2024 50.62 Mn
Mar 31, 2024 33.38 Mn
Mar 31, 2024 33.38 Mn
Dec 31, 2023 -25.13 Mn
Dec 31, 2023 -25.13 Mn